Biotherapy Treatment on Features of Microcrystalline Polyarthritis

Completed

• Conditions: Crystal-Induced Arthritis

• Registration Number: NCT04005625
• Lead Sponsor: University Hospital, Brest

Brief Summary

The study will involve adult patient who had received any biologic agent for microcrystalline disease in western France (Tours, Le Mans, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018.

Investigators will answer retrospectively a questionnaire that covers patient and disease data, biologic agent use, efficacy and adverse events.

Detailed Description

This is a retrospective multicentric study of all patients treated by biologic for microcrystalline disease in France in western France (Tours, Le Mans, Nantes, La Roche sur Yon, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018.

The investigators will collect all clinical (diagnosis of gout CCPD or hydroxyapatitis, tender and swollen joint count), biological (blood results: ESR, CRP, uric acid, synovial analysis), radiological data (X-rays performed and their description) .

Study Timeline

• Study First Submitted: 2019-03-29
• Study Start: 2019-05-01
• Study First Submitted QC: 2019-07-01
• Study First Posted: 2019-07-02
• Primary Completion: 2020-06-01
• Study Completion: 2020-06-01
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-11
• Last Update Posted: 2020-09-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

• Crystal- induced arthritis
• Treatment by biologic
• In western France

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment duration	one year	Duration of treatment by biologic in days

Secondary Outcome Measures

Name	Time	Method
number of synovitis	inclusion	number of synovitis on 44

Trial Locations

Locations (1)

CHRU de Brest; 🇫🇷 Brest, France